 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[34m                Passages:[0m
[34m                [0m[1;34m1[0m[34m. Drug HALOPERIDOL: The FDAHandler has responded with DO-NOT-KNOW to both inquiries about whether HALOPERIDOL increases or decreases the risk of angioedema. This indicates that the [0m
[34mFDA label for HALOPERIDOL does not specify any information regarding the drug's effect on the risk of angioedema. Therefore, it is not possible to determine from the FDA label data whether HALOPERIDOL[0m
[34mhas an impact on the risk of developing angioedema.[0m

[34m DO-NOT-KNOW[0m

[34mThe justification for this conclusion is that the FDA label for HALOPERIDOL, as per the responses from FDAHandler, does not contain information on the drug's effect on angioedema risk. Without this [0m
[34minformation, we cannot ascertain if HALOPERIDOL has any effect on the incidence of angioedema.[0m
[1;34m2[0m[34m. Drug THIOTHIXENE: I have attempted to retrieve information regarding the effect of thiothixene on the risk of angioedema from the FDAHandler multiple times, but have not received any relevant [0m
[34minformation. It appears that the FDA label for thiothixene does not specify whether it increases or decreases the risk of angioedema. Therefore, I cannot provide a definitive answer to this question [0m
[34mbased on FDA label data.[0m

[34m DO-NOT-KNOW[0m

[34mThe justification for this answer is that the FDAHandler has responded with DO-NOT-KNOW to inquiries about both an increase and a decrease in the risk of angioedema associated with thiothixene, [0m
[34mindicating that the FDA label does not contain this information.[0m
[1;34m3[0m[34m. Drug PIMOZIDE: DO-NOT-KNOW[0m

[34mThe FDA label for PIMOZIDE does not mention angioedema as a known risk or observed side effect, nor does it indicate that PIMOZIDE decreases the risk of angioedema. Therefore, based on the available [0m
[34mFDA label data, it is not possible to determine whether PIMOZIDE increases or decreases the risk of angioedema.[0m
[34m                ---------[0m
[34m                Does the typical antipsychotic category of drugs increase the risk of[0m
[34m                angioedema, decrease it, or is there no clear effect?[0m
[34m            [0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the typical antipsychotic category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The FDA label for HALOPERIDOL does not specify any information regarding the drug's effect on the risk of angioedema, leading to a DO-NOT-KNOW response."[0m[32m,[0m
[32m      [0m[32m"The FDA label for THIOTHIXENE also does not specify whether it increases or decreases the risk of angioedema, resulting in a DO-NOT-KNOW response."[0m[32m,[0m
[32m      [0m[32m"The FDA label for PIMOZIDE does not mention angioedema as a known risk or observed side effect, nor does it indicate that PIMOZIDE decreases the risk of angioedema, leading to a DO-NOT-KNOW [0m
[32mresponse."[0m[32m,[0m
[32m      [0m[32m"Since all three drugs in the typical antipsychotic category provided do not have information on their labels regarding the effect on angioedema risk, it is not possible to determine a clear [0m
[32meffect of the typical antipsychotic category on the risk of angioedema."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no clear effect of the typical antipsychotic category of drugs on the risk of angioedema based on the available information from the FDA labels."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the typical antipsychotic category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The FDA label for HALOPERIDOL does not specify any information regarding the drug's effect on the risk of angioedema, leading to a DO-NOT-KNOW response."[0m[34m,[0m
[34m      [0m[34m"The FDA label for THIOTHIXENE also does not specify whether it increases or decreases the risk of angioedema, resulting in a DO-NOT-KNOW response."[0m[34m,[0m
[34m      [0m[34m"The FDA label for PIMOZIDE does not mention angioedema as a known risk or observed side effect, nor does it indicate that PIMOZIDE decreases the risk of angioedema, leading to a DO-NOT-KNOW [0m
[34mresponse."[0m[34m,[0m
[34m      [0m[34m"Since all three drugs in the typical antipsychotic category provided do not have information on their labels regarding the effect on angioedema risk, it is not possible to determine a clear [0m
[34meffect of the typical antipsychotic category on the risk of angioedema."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no clear effect of the typical antipsychotic category of drugs on the risk of angioedema based on the available information from the FDA labels."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the typical antipsychotic category of drugs increase the risk of angioedema, decrease it, or is there no clear effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The FDA label for HALOPERIDOL does not specify any information regarding the drug's effect on the risk of angioedema, leading to a DO-NOT-KNOW response.[0m
[1;31m2[0m[31m. The FDA label for THIOTHIXENE also does not specify whether it increases or decreases the risk of angioedema, resulting in a DO-NOT-KNOW response.[0m
[1;31m3[0m[31m. The FDA label for PIMOZIDE does not mention angioedema as a known risk or observed side effect, nor does it indicate that PIMOZIDE decreases the risk of angioedema, leading to a DO-NOT-KNOW [0m
[31mresponse.[0m
[1;31m4[0m[31m. Since all three drugs in the typical antipsychotic category provided do not have information on their labels regarding the effect on angioedema risk, it is not possible to determine a clear effect [0m
[31mof the typical antipsychotic category on the risk of angioedema.[0m
[31m        -----[0m
[31m        Final answer: There is no clear effect of the typical antipsychotic category of drugs on the risk of angioedema based on the available information from the FDA labels.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m"The reasoning provided is flawed. The absence of information about a condition in the FDA data for all drugs in a category should lead to the conclusion that there is no effect for [0m
[32mthat drug category on the condition, rather than a 'do-not-know' response. Since none of the typical antipsychotic drugs mentioned [0m[32m([0m[32mhaloperidol, thiothixene, pimozide[0m[32m)[0m[32m have information on their labels[0m
[32mregarding the effect on angioedema risk, the correct conclusion should be that there is no effect of the typical antipsychotic category of drugs on the risk of angioedema, not that there is no clear [0m
[32meffect."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m"The reasoning provided is flawed. The absence of information about a condition in the FDA data for all drugs in a category should lead to the conclusion that there is no effect for [0m
[34mthat drug category on the condition, rather than a 'do-not-know' response. Since none of the typical antipsychotic drugs mentioned [0m[34m([0m[34mhaloperidol, thiothixene, pimozide[0m[34m)[0m[34m have information on their labels[0m
[34mregarding the effect on angioedema risk, the correct conclusion should be that there is no effect of the typical antipsychotic category of drugs on the risk of angioedema, not that there is no clear [0m
[34meffect."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Feedback: The reasoning provided is flawed. The absence of information about a condition in the FDA data for all drugs in a category should lead to the conclusion that there is no effect for [0m
[31mthat drug category on the condition, rather than a [0m[31m'do-not-know'[0m[31m response. Since none of the typical antipsychotic drugs mentioned [0m[1;31m([0m[31mhaloperidol, thiothixene, pimozide[0m[1;31m)[0m[31m have information on their labels[0m
[31mregarding the effect on angioedema risk, the correct conclusion should be that there is no effect of the typical antipsychotic category of drugs on the risk of angioedema, not that there is no clear [0m
[31meffect.[0m

[31m        If any flaws in the reasoning used to produce your[0m
[31m        answer were identified, you must try again.[0m
[31m        [0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does the typical antipsychotic category of drugs increase the risk of angioedema, decrease it, or is there no effect?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"The FDA label for HALOPERIDOL does not specify any information regarding the drug's effect on the risk of angioedema, leading to a DO-NOT-KNOW response."[0m[32m,[0m
[32m      [0m[32m"The FDA label for THIOTHIXENE also does not specify whether it increases or decreases the risk of angioedema, resulting in a DO-NOT-KNOW response."[0m[32m,[0m
[32m      [0m[32m"The FDA label for PIMOZIDE does not mention angioedema as a known risk or observed side effect, nor does it indicate that PIMOZIDE decreases the risk of angioedema, leading to a DO-NOT-KNOW [0m
[32mresponse."[0m[32m,[0m
[32m      [0m[32m"Given that none of the drugs in the typical antipsychotic category have information on their labels regarding an effect on angioedema risk, it can be concluded that there is no known effect of [0m
[32mthe typical antipsychotic category on the risk of angioedema."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"There is no effect of the typical antipsychotic category of drugs on the risk of angioedema based on the available information from the FDA labels."[0m[32m,[0m
[32m    [0m[32m"request"[0m[32m: [0m[32m"final_answer"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does the typical antipsychotic category of drugs increase the risk of angioedema, decrease it, or is there no effect?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"The FDA label for HALOPERIDOL does not specify any information regarding the drug's effect on the risk of angioedema, leading to a DO-NOT-KNOW response."[0m[34m,[0m
[34m      [0m[34m"The FDA label for THIOTHIXENE also does not specify whether it increases or decreases the risk of angioedema, resulting in a DO-NOT-KNOW response."[0m[34m,[0m
[34m      [0m[34m"The FDA label for PIMOZIDE does not mention angioedema as a known risk or observed side effect, nor does it indicate that PIMOZIDE decreases the risk of angioedema, leading to a DO-NOT-KNOW [0m
[34mresponse."[0m[34m,[0m
[34m      [0m[34m"Given that none of the drugs in the typical antipsychotic category have information on their labels regarding an effect on angioedema risk, it can be concluded that there is no known effect of [0m
[34mthe typical antipsychotic category on the risk of angioedema."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"There is no effect of the typical antipsychotic category of drugs on the risk of angioedema based on the available information from the FDA labels."[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does the typical antipsychotic category of drugs increase the risk of angioedema, decrease it, or is there no effect?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. The FDA label for HALOPERIDOL does not specify any information regarding the drug's effect on the risk of angioedema, leading to a DO-NOT-KNOW response.[0m
[1;31m2[0m[31m. The FDA label for THIOTHIXENE also does not specify whether it increases or decreases the risk of angioedema, resulting in a DO-NOT-KNOW response.[0m
[1;31m3[0m[31m. The FDA label for PIMOZIDE does not mention angioedema as a known risk or observed side effect, nor does it indicate that PIMOZIDE decreases the risk of angioedema, leading to a DO-NOT-KNOW [0m
[31mresponse.[0m
[1;31m4[0m[31m. Given that none of the drugs in the typical antipsychotic category have information on their labels regarding an effect on angioedema risk, it can be concluded that there is no known effect of the [0m
[31mtypical antipsychotic category on the risk of angioedema.[0m
[31m        -----[0m
[31m        Final answer: There is no effect of the typical antipsychotic category of drugs on the risk of angioedema based on the available information from the FDA labels.[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.USER [0m
 [1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mcategory_effect_tool[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"category_effect_tool"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"label"[0m[32m: [0m[32m"no-effect"[0m[32m,[0m
[32m    [0m[32m"confidence"[0m[32m: [0m[1;32m0.95[0m[32m,[0m
[32m    [0m[32m"probability"[0m[32m: [0m[1;32m0.0[0m[32m,[0m
[32m    [0m[32m"frequency"[0m[32m: [0m[32m"none"[0m[32m,[0m
[32m    [0m[32m"evidence"[0m[32m: [0m[32m"weak"[0m[32m,[0m
[32m    [0m[32m"justification"[0m[32m: [0m[32m"Based on the FDA label data for HALOPERIDOL, THIOTHIXENE, and PIMOZIDE, there is no information suggesting that these typical antipsychotic drugs have an effect on the risk of [0m
[32mangioedema. Therefore, it can be concluded that there is no known effect of the typical antipsychotic category on the risk of angioedema. The evidence is considered weak because it is based on the [0m
[32mabsence of reported effects rather than direct evidence of no effect."[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0moverall-effect-angioedema-typical antipsychotic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mcategory_effect_tool[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m
